An 8-week International, Multicentre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-release administered once daily as Monotherapy in the treatment of Adult Patients with Acute Bipolar Depression

Study identifier:D144CC00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An 8-week International, Multicentre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Sustained-release administered once daily as Monotherapy in the treatment of Adult Patients with Acute Bipolar Depression

Medical condition

mania

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria